Investment Thesis
BioCardia faces severe financial distress with negative shareholders' equity of -$1.1M, indicating technical insolvency. The company has zero revenue, negative operating cash flow of -$1.7M, and a critical liquidity crisis with current ratio of 0.41x, meaning current liabilities are 2.4x current assets with less than one year of cash runway at current burn rates.
Strengths
- Minimal capital expenditure requirements suggests asset-light business model
- Retains $951K in cash reserves providing short-term operational window
- Operating in biological products sector which may contain proprietary technology or pipeline value
Risks
- Negative stockholders' equity of -$1.1M indicates technical insolvency and balance sheet deterioration
- Current ratio of 0.41x signals acute liquidity crisis with inability to meet short-term obligations
- Zero revenue generation with -100% YoY decline indicates complete loss of commercial traction
- Operating cash burn of -$1.7M with limited runway suggests imminent need for capital infusion or restructuring
- Total liabilities exceed total assets by $1.1M creating existential solvency risk
Key Metrics to Watch
- Monthly cash burn rate and time-to-depletion of cash reserves
- Any revenue generation or customer contracts
- Capital raising activities or equity financing announcements
- Liability reduction or debt restructuring efforts
- Strategic partnership, merger, or acquisition activity
Financial Metrics
Revenue
0.0
Net Income
-2.3M
EPS (Diluted)
$-0.21
Free Cash Flow
-1.7M
Total Assets
1.7M
Cash
951.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-132.0%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.41x
Quick Ratio
0.41x
Debt/Equity
N/A
Debt/Assets
162.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T08:01:35.761396 |
Data as of: 2026-03-31 |
Powered by Claude AI